Prothena PRTA 深 沪
等待开盘 07-07 09:30:00 美东时间
9.50
-0.190
-1.96%
华盛通- 最 高9.84
- 今 开9.65
- 成交量 40.37万股
- 最 低 9.465
- 昨 收 9.69
- 总市值 4.97亿
- 52周最高 11.80
- 市盈率 静 --
- 换手率 0.77%
- 52周最低 6.16
- 委 比 84.62%
- 总股本 5235.32万
- 历史最高 79.749
- 量 比 0.56
- 振 幅 3.87%
- 历史最低 4.32
- 每 手 1
- 风险率 1.18%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多阿尔茨海默病概念股盘中小幅上扬 礼来涨6.2% 渤健涨6.1% Prothena涨3.5%
阿尔茨海默病相关个股在常规交易时段走高。 相关个股涨幅数据：礼来上涨6.2%，渤健涨幅达6.1%，Prothena攀升3.5%。 译文内容由第三方软件翻译。 声...
06-26 22:06
UPDATED: Watching Prothena; Shares Spike Higher, Form4 Filing Shows William P. Scully Bought 100,000 Shares At An Average Price Of $9.81/Share
https://www.sec.gov/Archives/edgar/data/1559053/000104546326000004/xslF345X06/primary_doc.xml
05-27 03:00
美股大行评级 | 爱彼迎、Affirm、CoreWeave、Datadog、微芯科技等获多家大行上调目标价；HubSpot惨遭14家大行下调目标价
今日重点评级关注：HC Wainwright & Co.：维持Artiva Biotherapeutics"买入"评级，目标价从15美元升至35美元；韦德布什：维持Cullinan Therapeutics"跑赢大市"评级，目标价从36美元升至37美元
05-11 15:43
Citizens Maintains Market Outperform on Prothena Corp, Raises Price Target to $20
Citizens analyst Jason N. Butler maintains Prothena Corp (NASDAQ:PRTA) with a Market Outperform and raises the price target from $19 to $20.
05-08 23:15
Prothena Announces Coramitug Amyloid Depleter Antibody Receives FDA's Fast Track Designation To Treat ATTR Amyloidosis With Cardiomyopathy
Prothena Corporation plc (NASDAQ:PRTA) today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation to coramitug, a potential best-in-class amyloid depleter antibody currently in
04-28 04:12
新浪财经ESG：Prothena Corporation plc MSCI（明晟）ESG评级调降至BBB
新浪财经ESG评级中心提供包括资讯、报告、培训、咨询等在内的14项ESG服务，助力上市公司传播ESG理念，提升ESG可持续发展表现。点击查看【 ESG评级中...
03-24 10:28
Prothena Announces $100 Million Share Repurchase Program
Prothena ( ($PRTA) ) has shared an announcement. On February 27, 2026, Prothena...
02-28 06:42
Prothena shares are trading higher after the company announced a $100 million share buyback.
Prothena shares are trading higher after the company announced a $100 million s...
02-28 05:17
美股大行评级 | 潜在涨幅214.14%！HC Wainwright & Co.：Ardelyx获机构升目标价至18美元，维持"买入"评级
今日重点评级关注：HC Wainwright & Co.：维持Ardelyx"买入"评级，目标价从10美元升至18美元；Truist Securities：维持Praxis Precision Medicine"买入"评级，目标价从500美元升至700美元
02-23 08:56
